Clazakizumab Biosimilar - Research Grade

ICH5063-100mg

Clazakizumab Biosimilar - Research Grade

Detects human IL-6. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Clazakizumab.

5000 €

ICH5063-10mg

Clazakizumab Biosimilar - Research Grade

Detects human IL-6. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Clazakizumab.

1145 €

ICH5063-1mg

Clazakizumab Biosimilar - Research Grade

Detects human IL-6. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Clazakizumab.

300 €

ab-131-ustekinumab

Ustekinumab Biosimilar - Research Grade

526.25 €

ab-131-vedolizumab

Vedolizumab Biosimilar - Research Grade

526.25 €

CD0-M36

Rituximab biosimilar–Research Grade

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

724.2 €